This exit follows an FDA approval of the company’s Agili-C implant for the treatment of cartilage and osteochondral defects.
CartiHeal’s mission is to treat millions of people suffering from knee cartilage defects and osteoarthritis, CartiHeal’s Agili-C, is a coral-based implant that is intended for the treatment of damaged cartilage, by encouraging growth of a patient’s cartilage and bone. The company was founded in Incentive, Peregrine Ventures Incubator.
